The drug recently approved to be used along with phenteramine in the management of obesity is
**Question:** The drug recently approved to be used along with phenteramine in the management of obesity is:
A. Orlistat
B. Naltrexone-Bupropion
C. Contrave (Naltrexone-Bupropion)
D. Qsymia (Phentermine-Topiramate)
**Correct Answer:** D. Qsymia (Phentermine-Topiramate)
**Core Concept:**
Phenteramine is a sympathomimetic amine, a class of drugs used for weight loss. It is a selective Ξ±2-adrenergic receptor antagonist, which increases central nervous system stimulation, leading to decreased appetite and increased energy expenditure. In recent years, the combination therapy with other drugs has been developed to enhance the efficacy of phenteramine and improve outcomes in the management of obesity.
**Why the Correct Answer is Right:**
Qsymia, a combination of Phentermine and Topiramate, is a recently approved drug used in conjunction with phenteramine for the treatment of obesity. Phentermine is a sympathomimetic amine, a central nervous system stimulant, which increases central nervous system stimulation. Topiramate is an anticonvulsant drug that also acts as a mood stabilizer. When combined, these drugs work together to suppress appetite, increase energy expenditure, and improve weight loss outcomes.
**Why Each Wrong Option is Incorrect:**
A. Orlistat (Xenical) is an inhibitor of pancreatic lipase, preventing the absorption of dietary fats in the gastrointestinal tract, reducing caloric intake. Orlistat is not a sympathomimetic amine and does not work synergistically with phenteramine.
B. Naltrexone is an opioid antagonist used in the treatment of alcohol and opioid addiction. It is not a sympathomimetic amine and does not work synergistically with phenteramine.
C. Contrave (Bupropion-Naltrexone) is a combination of bupropion (an antidepressant) and naltrexone (an opioid antagonist). While Contrave is a combination therapy, it is not a sympathomimetic amine and does not directly work synergistically with phenteramine.
**Clinical Pearl:**
A combination of Phentermine and Topiramate (Qsymia) is a recently approved drug for the management of obesity. By targeting appetite suppression and energy expenditure, this combination therapy can improve weight loss outcomes and provide better control over obesity management. Always consult with a healthcare professional before initiating any medication for weight loss and consider the potential side effects, drug interactions, and individual patient factors when choosing a suitable treatment option.